Luminex Corporation (LMNX)

22.93 +0.15  +0.66%  May 29, 8:00PM Go Pro
Watch this stock
View Full Chart LMNX Price Chart

Key Stats

Market Cap 958.47M
Revenue Growth 12.60%
Profit Margin 7.24%
Earnings Yield 1.35%
Dividend Yield 0.00%
Earnings Per Share TTM 0.31
PE Ratio 73.97
Price / Sales Ratio 5.050
52 Week High 25.16
52 Week Low 18.33
Beta 0.5496
View Pro Ratings Details

YCharts Pro Ratings

Go Pro.
Learn More
  • Pro Value Score Go Pro
  • Pro Fundamental Score Go Pro
  • Pro Valuation from Historical Multiples Go Pro

News

May 22 LUMINEX CORP Files SEC form 8-K/A, Change in Directors or Principal Officers, Submiss...
May 17 LUMINEX CORP Files SEC form 8-K, Change in Directors or Principal Officers, Submissio...
May 17 recommends $LMNX as a positive growth company. by MarkeScope
May 08 LUMINEX CORP Financials
May 03 New Star Analyst Rankings for Luminex Corporation
May 03 Mixed 1Q for Luminex, Profits Down
May 03 Mixed 1Q for Luminex, Profits Down - Analyst Blog Zacks
May 02 GARP Research Maintains a 'Buy' on Luminex (LMNX); Q1 Review Street Insider
May 01 LUMINEX CORP Files SEC form 10-Q, Quarterly Report
May 01 Luminex Meets on Revenues, Misses on EPS Fool
Apr 30 $LMNX has the volume, now let's see the follow through by Momochaser
Apr 29 my favorite looking healtcare setup i just found on @stocktwits is $LMNX ...what do we know other than price and vol working. thx by howardlindzon
Apr 29 RT @chartly RT @traderdigs $LMNX http://stks.co/3ZUX broke from cup n handle by howardlindzon
Apr 29 RT @OptionsHawk $LMNX - Luminex - Monthly Strong Trend, 11.8 Days to Cover Short, 4/30 Earnings - Impressive Growth http://stks.co/3ZUO by howardlindzon

Profile

Exchange: NASDAQGM       Sector: Healthcare       Industry: Medical Instruments & Supplies

Luminex Corporation is a biotechnology company based in Austin, Texas, with offices in Australia, Toronto and the Netherlands. Luminex develops, manufactures and markets proprietary biological testing technologies with applications throughout the life-sciences industry. The company operates its business through two segments: Technology and Strategic Partnerships (TSP) and Assays and Related Products (ARP). Patrick J. Balthrop, Sr. has served as Luminex's President and Chief Executive Officer since May, 2004. It serves pharmaceutical companies, clinical laboratories, research institutions, and medical institutions in the United States, Europe, Asia, Canada, and Australia. Luminex was recently recognized by Forbes magazine as one of the top 25 fastest growing technology companies in the US. The company was founded in 1995.

1 Year Total Return Performance

This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Luminex Corporation is up 15.93% over the last year vs S&P 500 Total Return up 2.32%, Mesa Laboratories up 52.95%, and Bio-Rad Laboratories down 17.34%.

  • LMNX Total Returns
  • ^SPXTR Total Returns
  • MLAB Total Returns
  • BIO Total Returns

Fundamentals

Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.

Income Statement View Statement

Balance Sheet View Statement

Get Quote for

Pro Strategies Featuring LMNX

Did Luminex Corporation make it into our Pro Portfolio Strategies?

Start your YCharts Pro membership now to find out.

LMNX Charts

Recent Quotes

Symbol Price Chg Chg % Market Cap
LMNX 22.93 +0.15 +0.66% 958.47M
LMLP 1.92 +0.00 +0.00% 54.20M
LMCB 85.35 +1.33 +1.58% 847.53M
LMCA 85.46 +1.02 +1.21% 9.583B
LMAT 5.30 +0.13 +2.50% 81.67M
LM 26.14 +0.62 +2.43% 3.653B
LLY 41.30 +0.19 +0.46% 47.92B
LKQX 36.28 +0.75 +2.11% 5.345B
LKFN 25.61 +0.24 +0.95% 417.44M
LIZ 13.00 +0.00 +0.00% 1.313B
You must be signed in to use watchlists.
Sign In or Register
Create Watchlist from Stock Quotes
Close